Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

Leukemia

Volumn 30, Issue 5, 2016, Pages 1094-1102

  Mitra, A K ^a   Mukherjee, U K ^a   Harding, T ^a   Jang, J S ^b   Stessman, H ^a   Li, Y ^b   Abyzov, A ^b   Jen, J ^b   Kumar, S ^b   Rajkumar, V ^b   Van Ness, B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IXAZOMIB; OPROZOMIB; TRANSCRIPTOME; PROTEASOME INHIBITOR;

ARTICLE; BIOINFORMATICS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; FLAM76 CELL LINE; GENE EXPRESSION PROFILING; HIERARCHICAL CLUSTERING ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KP6 CELL LINE; LP1 CELL LINE; MM1 144 CELL LINE; MMM1 CELL LINE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; OCI MY1 CELL LINE; PE2 CELL LINE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE CELL ANALYSIS; SKMM1 CELL LINE; STATISTICAL ANALYSIS; TRANSCRIPTOMICS; TREATMENT RESPONSE; U266 CELL LINE; UTMC2 CELL LINE; ALGORITHM; BIOLOGY; GENETIC VARIATION; GENETICS; MACHINE LEARNING; PROCEDURES; STATISTICS; TUMOR CELL LINE;

ALGORITHMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; GENETIC VARIATION; HUMANS; MACHINE LEARNING; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; SINGLE-CELL ANALYSIS; STATISTICS AS TOPIC; TRANSCRIPTOME;

EID: 84955600532     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.361     Document Type: Article

References (53)

1. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 226-235.
2. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011; 29: 1916-1923.
3. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 3337-3344.
4. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-959.
5. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011; 11: 254-284.
6. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013; 121: 893-897.
7. Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabro L et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res 2014; 38: 1-9.
8. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463.
9. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
10. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429-435.
11. Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol 2012; 88: 93-117.
12. Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood 2008; 112: 2177-2178.
13. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010; 20: 68-80.
14. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
15. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013; 119: 3034-3042.
16. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.
17. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
18. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28: 1705-1715.
19. Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W et al. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol 2015; 16: 015-0692-3.
20. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344: 1396-1401.
21. Ennen M, Keime C, Kobi D, Mengus G, Lipsker D, Thibault-Carpentier C et al. Single-cell gene expression signatures reveal melanoma cell heterogeneity. Oncogene 2015; 34: 3251-3263.
22. Zhan F, Barlogie B, Mulligan G, Shaughnessy Jr JD, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008; 111: 968-969.
23. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
24. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26: 2406-2413.
25. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
26. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 2013; 12: 1140-1150.
27. Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One 2013; 8: e77608.
28. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y et al. Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther 2011; 339: 9-23.
29. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd edn. Springer: New York, NY, USA, 2009.
30. Barzi F, Woodward M. Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies. Am J Epidemiol 2004; 160: 34-45.
31. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B 1977; 39: 1-38.
32. Honaker J, King G, Blackwell M, Amelia II. A program for missing data. J Stat Softw 2011; 45: 1.
33. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Ser B 2011; 73: 273-282.
34. Breiman L. Random Forests. Mach Learning 2001; 45: 5-32.
35. Steinwart I, Christmann A. Support Vector Machines. Springer: New York, NY, USA, 2008.
36. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
37. Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognit 1997; 30: 1145-1159.
38. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012; 19: 99-115.
39. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
40. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177-3188.
41. Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 2005; 90: 1305-1308.
42. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
43. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27: 473-481.
44. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390.
45. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
46. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
47. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
48. Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A et al. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia 2014; 28: 2263-2267.
49. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoprolifera-tive disorders and its correlation with normal B-cell maturation. Leukemia 2005; 19: 1376-1383.
50. Rasmussen AM, Blomhoff HK, Stokke T, Horejsi V, Smeland EB. Cross-linking of CD53 promotes activation of resting human B lymphocytes. J Immunol 1994; 153: 4997-5007.
51. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 11: 361-374.
52. Man SM, Zhu Q, Zhu L, Liu Z, Karki R, Malik A et al. Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell 2015; 162: 45-58.
53. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367-380.